Abstract 16P
Background
First-line therapy with PD-1 blockade and chemotherapy is recommended for human epidermal growth factor receptor 2 (HER2)–negative patients with advanced gastric cancer (GC) or gastroesophageal junction cancer (GEJC), but the clinical outcomes of this approach is very variable. Predictive biomarkers are thus urgently required, here we investigated the predictive ability of exosomal PD-L1 and lactate levels in advanced GC or GEJC patients.
Methods
This prospective study (RENMIN-221) enrolled 68 advanced GC or GEJC patients receiving first-line PD-1 blockade and standard chemotherapy from January 2022 to March 2023. Exosomes were isolated by ultracentrifugation method from plasma prior to therapy. PD-L1 and lactate levels of the recovered exosomes were determined by enzyme-linked immunosorbent assay (ELISA), and peripheral blood was obtained before each cycle of treatment. The composition of peripheral CD3+ T cells, CD4+T cells, CD8+T cells, regulatory T (CD4+CD25+CD127low, Treg) cells, and the expression of their PD-1 were assessed by flow cytometry.
Results
Compared to the responders (CR+PR), exosomal PD-L1 (P=0.014) and lactate (P=0.012) was significantly higher than that of the non-responders (SD+PD) before the treatment. The receiver operating characteristic (ROC) curve showed that the combination of exosomal PD-L1 and lactate best distinguished responders from non-responders (area under the curve [AUC]: 0.787 vs. 0.748 vs. 0.706) among all the parameters tested. Combining predictor lower than -0.274 was associated with a better response to the therapy by ORR (82.1% vs. 30.0%, P<0.001), and mPFS (13.8 vs 5.5 months, P<0.001). Exosomal PD-L1 levels were signifcantly correlated with the frequency of CD8+T cells before treatment (P=0.025). And exosomal lactate was associated with less CD8+T cells and more Treg cells after treatment, while exosomal PD-L1was associated with more Treg cells and more PD-1+ Treg cells after treatment.
Conclusions
Exosomal PD-L1 and lactate levels could predict clinical outcomes, which provide accurate and convenient biomarkers in advanced GC or GEJC patients receiving first-line PD-1 blockade combined with chemotherapy.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
101P - Progression-Free Survival is an acceptable surrogate endpoint for chemo-immunotherapy combinations in Cervical Carcinoma, an EORTC Young GCG study
Presenter: Ramon Yarza
Session: Poster Display
102P - Interim safety analysis of a phase 2 trial of cisplatin-sensitized radiation therapy and pembrolizumab for unresectable vulvar cancer
Presenter: Oladapo Yeku
Session: Poster Display
103P - Long-term survivorship rates among previously treated patients with advanced renal cell carcinoma (aRCC) achieving objective response with nivolumab
Presenter: Saby George
Session: Poster Display
105P - Preliminary efficacy and safety results from ‘ReBirth’, a phase II study of risk-based bladder-sparing therapy for MIBC.
Presenter: Yijun Shen
Session: Poster Display
106P - Treatment Sequencing in PD-L1-Positive Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC): Exploratory Analysis of the Phase 3 KEYNOTE-048 Study
Presenter: Amanda Psyrri
Session: Poster Display
108P - Real-world (RW) effectiveness and safety of adjuvant nivolumab (NIVO) in patients (pts) with melanoma in Belgium and Luxembourg: PRESERV MEL
Presenter: Bart Neyns
Session: Poster Display
109P - Prognosis of patients with metastatic melanoma with initial stable disease during treatment with anti-PD-1 monotherapy
Presenter: Inge Noringriis
Session: Poster Display
110P - Outcomes of CUPem: A prospective Phase II multicentre clinical Trial of Pembrolizumab in patients with pre-treated Cancer of Unknown Primary
Presenter: Harpreet Wasan
Session: Poster Display
111P - Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma compared to patients with advanced solid tumours
Presenter: Ciro Celsa
Session: Poster Display